Anlotinib Combined With mXELIRI as Second-line Treatment of Advanced Colorectal Cancer

  • End date
    Dec 31, 2024
  • participants needed
  • sponsor
    Guangzhou University of Traditional Chinese Medicine
Updated on 12 September 2021


  1. Determine the maximum tolerable dose (MTD) and / or phase II recommended dose (RP2D) of the allotinib combined mXELIRI protocol.
  2. To evaluate the safety and tolerance of the combination of anlotinib and mXELIRI in the second-line treatment of patients with advanced colorectal cancer


This study consists of two phases, the dose-escalation phase, and the expansion phase. 9-12 patients with advanced colorectal cancer will be included in the dose escalation study. Patients who met the inclusion criteria would be treated with anlotinib QD for 2 weeks, and then stopped for 1 week, combined with mXELIRI. Every 21 days was a treatment cycle. Safety information was collected until the disease progression or intolerable toxicity, so as to determine the MTD and / or RP2D of anlotinib combined with irinotecan in patients with advanced colorectal cancer. The study adopted the traditional 3+3 design .

The primary outcome in dose-expansion phase was objective response rate(ORR).

Condition Advanced Colorectal Cancer
Treatment Anlotinib Hydrochloride
Clinical Study IdentifierNCT05035914
SponsorGuangzhou University of Traditional Chinese Medicine
Last Modified on12 September 2021


Yes No Not Sure

Inclusion Criteria

ECOG performance status (PS) 0-1
The expected survival time is not less than 12 weeks
Patients with stage IV colorectal cancer confirmed by pathology or imaging have measurable lesions (according to RECIST 1.1, the long diameter of tumor lesions on CT scan is greater than or equal to 10 mm, the short diameter of lymph node lesions on CT scan is greater than or equal to 15 mm, and the measurable lesions have not received radiotherapy, freezing and other local treatment)
First line patients with advanced or intolerant colorectal cancer treated with bevacizumab combined with oxaliplatin (FOLFOX or capeox, etc.)
The function of main organs was normal (in accordance with the chemotherapy standard)
Women of childbearing age must have taken reliable contraceptive measures or conducted pregnancy test (serum or urine) within 7 days before enrollment, and the result is negative, and they are willing to use appropriate contraceptive methods during the test period and 8 weeks after the last administration of the test drug. For men, it is necessary to agree to use appropriate contraceptive methods or surgical sterilization during the trial period and 8 weeks after the last administration of the trial drug
The subjects volunteered to join the study and signed informed consent, with good compliance and follow-up

Exclusion Criteria

The histological type was mucinous adenocarcinoma or ovarian implant metastasis
First line patients with irinotecan treatment
Patients who had been treated with anlotinib hydrochloride capsules in the past
Symptomatic brain metastases (patients with stable symptoms and completed treatment 21 days before enrollment can be enrolled, but no cerebral hemorrhage symptoms should be confirmed by brain MRI, CT or venography evaluation)
Patients with hypertension who could not be well controlled by single antihypertensive drug treatment (systolic blood pressure 150 mmHg, diastolic blood pressure 100 mmHg); Or use two or more antihypertensive drugs to control blood pressure
The patient also had more than 1 degree of adverse reactions (except hair loss, neurotoxicity more than 2 degrees) which could not be alleviated due to previous treatment
They have the following cardiovascular diseases: myocardial ischemia or myocardial infarction above grade II, poorly controlled arrhythmias (including QTc interval 450 ms for male and 470 MS for female); According to NYHA criteria, grade - cardiac insufficiency, or left ventricular ejection fraction (LVEF) < 50% by echocardiography
Abnormal coagulation function (INR > 1.5 or PT > ULN + 4 seconds or APTT > 1.5 ULN), bleeding tendency or receiving thrombolysis or anticoagulation therapy
There were significant clinical bleeding symptoms or clear bleeding tendency in the first 3 months, such as gastrointestinal bleeding, hemorrhagic hemorrhoids, hemorrhagic gastric ulcer, baseline fecal occult blood + + or above, or vasculitis
Arteriovenous thrombotic events occurred in the first 12 months, such as cerebrovascular accident (including transient ischemic attack, cerebral hemorrhage, cerebral infarction), deep venous thrombosis and pulmonary embolism
Known hereditary or acquired bleeding and thrombotic tendency (such as hemophilia, coagulation dysfunction, thrombocytopenia, hypersplenism, etc.)
Wound or fracture that has not been cured for a long time (pathological fracture caused by tumor is not included)
Patients in the study group had undergone major surgery or severe traumatic injury, fracture or ulcer within 4 weeks
There are obvious factors affecting oral drug absorption, such as inability to swallow, chronic diarrhea and intestinal obstruction
Abdominal fistula, gastrointestinal perforation or abdominal abscess occurred within 6 months before admission
Urine routine showed that urine protein was + +, and 24-hour urine protein was more than or equal to 1.0 G
Serous effusion (including pleural effusion, ascites and pericardial effusion) with clinical symptoms and requiring symptomatic treatment
Asymptomatic serous effusion can be included in the group, symptomatic serous effusion after active symptomatic treatment (can not use anticancer drugs for serous effusion treatment), patients who can be included in the group after the judgment of the researchers are allowed to be included in the group
Active infections need antimicrobial treatment (for example, the use of antibiotics and antiviral drugs, excluding chronic hepatitis B anti hepatitis B treatment, antifungal treatment)
There was active hepatitis B (HBV DNA > 2000IU/mL or 104 copy number /mL) or hepatitis C (hepatitis B antibody positive, and HCV RNA was higher than the lower limit of analysis)
Those who have a history of psychotropic drug abuse and can not give up or have mental disorders
Those who participated in clinical trials of other anti-tumor drugs within 4 weeks before enrollment
Previous or other untreated malignancies were cured except for basal cell carcinoma, cervical carcinoma in situ and superficial bladder cancer
Those who received strong CYP3A4 inhibitor treatment within 7 days before randomization, or those who received strong CYP3A4 inducer treatment within 12 days before participating in the study
Pregnant or lactating women; Patients with fertility are unwilling or unable to take effective contraceptive measures
The researcher judges other situations that may affect the clinical research and the judgment of research results
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact



Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note